Milk Beta Caseins on Digestive Discomfort, Gastric Emptying
Public ClinicalTrials.gov record NCT07884123. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Comparing the Gastro-Intestinal Transit Time of Commercial Milk Containing A1 β-casein in Presence of the Opioid Antagonist Naloxone
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
A1 and A2 β-casein are genetic variants of β-casein in cow's milk that differ by a single amino acid at position 67. Digestion of A1 β-casein may result in greater release of beta-casomorphin-7 (BCM-7), an opioid peptide that may influence gastrointestinal function. Previous work from our group in lactose maldigesters found differences in gastric emptying following consumption of A1/A2 milk compared with A1 protein-free (A1PF) milk. This randomized, masked, crossover study evaluated whether opioid receptor blockade with oral naloxone influenced gastric emptying following consumption of A1/A2 milk compared with A1PF milk in lactose maldigesters. Participants consumed each milk treatment with 2 mg oral naloxone during separate study visits. Gastric volume was measured using magnetic resonance imaging (MRI) over 120 minutes, and gastrointestinal symptoms were assessed. The study was designed to investigate whether opioid receptor signaling contributes to differences in gastric emptying between A1/A2 milk and A1PF milk.
Study identification
- NCT ID
- NCT07884123
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Not applicable
- Enrollment
- 10 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years to 65 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jan 30, 2025 (Actual)
- Primary completion
- Jan 30, 2026 (Actual)
- Completion
- Jan 30, 2026 (Actual)
- Last update posted
- Oct 20, 2026
2025 – 2026
United States locations
- U.S. sites
- 1
- U.S. states
- 1
- U.S. cities
- 1
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Clinical Research Center | West Lafayette | Indiana | 47907 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT07884123, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Oct 20, 2026 · Synced Oct 21, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT07884123 live on ClinicalTrials.gov.